PAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer. Background: Early detection and monitoring the progress of common ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback